TP53 and colorectal carcinoma: Seroreactivity to p53- and p63-derived proteoforms showed significant differences for most of the proteoforms tested in comparison with the control, the CRC, and the premalignant individuals’ plasmas, according to the threshold (cut-off value) obtained for all comparisons (Table 2).